Kurzius Lawrence Erik purchased $539K of COO

Cooper Companies (COO) ended its 9-month effort to sell CooperSurgical after bids undervalued the business, according to management. The stock dropped 15% to a 52-week low near $51 after a Q3 miss and cut outlook. The company's core contact lens business, CooperVision, posted flat organic revenue growth, contributing to the guidance cut. Management authorized a $1B share repurchase program, while Bank of America questioned the valuation. COO reported record Q3 free cash flow of $273M.

The Cooper Companies (COO) lowered its fiscal 2026 profit and revenue forecasts due to weaker-than-expected contact lens demand, with adjusted EPS now expected at $4.51–$4.55 and revenue at $4.23–$4.25 billion. Q3 revenue was $1.07 billion, missing estimates, though adjusted EPS beat at $1.15. The company cited U.S. channel inventory reductions as a key factor and decided to retain CooperSurgical.

Cooper Companies (COO) reported Q3 FY2026 revenue of $1.066B, up 1%, and adjusted EPS of $1.15, up 4%. The company spent $339.1M on share buybacks and has $1.5B remaining in repurchase capacity. Fertility segment growth and strong cash flow offset weakness in CooperVision, which saw flat organic growth and revenue declines in Americas and Asia Pacific. Gross margin improved to 67% on a GAAP basis, while adjusted operating margin rose 30 basis points to 26%.

Cooper Companies (COO) fell 14.67% after reporting Q3 revenue of $1.07B and Q4 guidance below estimates. Freeport-McMoRan (FCX) dropped 6.59% due to White House uncertainty on copper tariffs. Baker Hughes (BKR) declined 6.66% despite raising its full-year revenue guidance to $28.5B-$30.3B.

CooperCompanies reported Q2 revenue of $1.07B (flat YoY, 2.9% miss) and adjusted EPS of $1.15 (2.7% beat). Full-year guidance was lowered to $4.24B revenue and $4.53 EPS. The company reduced U.S. inventory and retained CooperSurgical after a strategic review. Management plans to invest in sales and R&D, aiming for future growth and improved margins.

CooperCompanies (COO) shares dropped 13.9% after Q3 earnings beat estimates but Q4 guidance fell short of expectations. The company also decided to retain CooperSurgical, removing a potential deal catalyst. U.S. distributor destocking is expected to continue impacting CooperVision's Q4 performance.